Does Retatrutide Cause Hair Loss? What the Research and Clinical Trial Reports Indicate 

Hair shedding has been reported in the broader context of weight-loss treatments, but current retatrutide evidence does not show whether it results directly from the compound. It may instead be related to rapid weight loss, metabolic stress, or changes in nutritional intake.

This article will explore what retatrutide trials report about hair loss, why accelerated weight reduction may disrupt the hair growth cycle, how findings compare with other weight-loss drugs, and what research suggests about prevention and regrowth. Doctor Medica’s staff can assist licensed professionals with sourcing questions about retatrutide — those looking to buy retatrutide for research purposes are welcome to reach out directly.

Key Takeaways

• Published Phase 2 and Phase 3 reports have not identified hair loss as a prominent direct adverse effect of retatrutide.
• Rapid weight loss and reduced nutritional intake can contribute to telogen effluvium, a temporary form of diffuse hair shedding.
• Hair follicles usually remain intact during telogen effluvium, allowing regrowth after the underlying metabolic or nutritional stress resolves.

About: Doctor Medica is your trusted all-in-one supplier, offering a range of high-quality medical injectables and supplies. We offer a worry-free experience in searching for the best and most popular products on the market, like retatrutide. Whether for health professionals, plastic surgeons, dermatologists, licensed estheticians, or other specialists, we can offer genuine, brand-name products you may need. With Doctor Medica, we prioritize serving you better to improve the patient’s quality of life.

Is Hair Loss a Direct Side Effect of Retatrutide? What Trial Reports Show

Current evidence does not show that retatrutide directly damages hair follicles or causes a distinct form of drug-induced alopecia. Hair loss was not among the main adverse events highlighted in the Phase 2 obesity trial, and Lilly’s public TRIUMPH-1 Phase 3 results likewise did not identify it as a leading finding.[1][2]

That does not mean no participants experienced shedding. Public trial summaries generally focus on the most common or clinically significant adverse events and may not provide rates for every less frequent outcome. Until complete Phase 3 safety tables and peer-reviewed analyses are available, a reliable retatrutide-specific rate of hair loss cannot be established.

Any discussion of retatrutide hair loss side effects should distinguish between direct drug-induced alopecia and shedding associated with rapid weight loss. The latter may occur when substantial physiological change, reduced calorie intake, or nutritional deficiencies push more hair follicles into the resting phase. Based on the evidence available so far, secondary weight-loss-related shedding appears more plausible than a direct toxic effect on hair follicles, although causality has not been confirmed.[3][4]

Why Does Rapid Weight Loss Cause Hair Loss? The Metabolic Mechanism

Severe calorie restriction and rapid weight loss can place the body under metabolic stress. When energy or nutrient intake becomes inadequate, resources may be directed away from less essential functions, including active hair growth.[3][4]

The resulting hair loss may resemble telogen effluvium, a diffuse, nonscarring form of shedding that can follow a major physiological or metabolic stressor. Rapid weight loss, restrictive diets, illness, surgery, and nutritional deficiencies are all recognized triggers.[3][6]

Hair normally passes through four stages: anagen, the active growth phase; catagen, the transition phase; telogen, the resting phase; and exogen, when the hair is released. In telogen effluvium, more follicles than usual enter the resting phase simultaneously. Because the affected hairs remain in telogen before shedding, noticeable hair loss often begins weeks or months after the original trigger rather than immediately.[6] This delay can make the cause difficult to identify. A participant may associate shedding with a recent retatrutide dose even though the follicular change began earlier, during a period of accelerated weight loss.

Healthy hair growth also depends on adequate intake of protein, iron, zinc, energy, and other vitamins and minerals. Significant appetite reduction or restrictive eating may make these needs harder to meet, especially when weight is falling quickly.[3][4] However, iron or vitamin supplements should be used only when a clinical evaluation or laboratory testing identifies a deficiency, rather than as a routine preventive measure.

What Does the Research Say About Hair Loss While on Retatrutide?

Publicly available Phase 2 retatrutide publications do not identify hair loss as a prominent adverse event. The 48-week obesity trial focused on weight outcomes and reported that the most common adverse events followed the general tolerability pattern seen in incretin-based research, without highlighting hair loss as a leading finding. [2]

Lilly’s May 2026 TRIUMPH-1 update reported results from 2,339 adults with obesity or overweight. Participants receiving retatrutide achieved average weight reductions of up to 28.3% at 80 weeks, while a prespecified extension reported an average reduction of up to 30.3% at 104 weeks among selected participants with a higher baseline BMI. Hair loss was not included in the public list of the trial’s most common adverse events. [1]

This creates an important distinction: retatrutide studies have documented a magnitude and pace of weight reduction that could plausibly trigger telogen effluvium in susceptible individuals, while publicly reported data have not yet demonstrated that retatrutide directly causes follicular injury or a distinct alopecia pattern. The timing of hair loss also differs from how long it takes for retatrutide to work in terms of metabolic or body-weight outcomes — shedding linked to physiological stress may appear several months after weight loss begins, even when other changes become measurable earlier. [1][3][6]

More complete Phase 3 safety data will be needed before firm conclusions can be drawn about a retatrutide-specific hair-loss pattern.

Does Retatrutide Exacerbate Hair Loss More Than Other Weight-Loss Drugs?

There is not enough direct evidence to determine whether retatrutide is more likely to worsen hair loss than semaglutide, tirzepatide, or other weight-loss medications. Retatrutide remains investigational, and publicly available studies do not include head-to-head comparisons of alopecia rates.[1][2]

Evidence from approved incretin-based therapies offers some useful context. According to the FDA prescribing information for Wegovy®, hair loss was reported in 3% of treated adults, compared with 1% of participants who received placebo, and in 4% of participants in a pediatric obesity study.[5] A 2026 systematic review of GLP-1-related therapies also found that hair-loss signals were most commonly reported with semaglutide and tirzepatide. Telogen effluvium and androgenetic alopecia were the main patterns identified, and rapid weight loss was considered a possible contributing factor. The authors stressed, however, that prospective studies are still needed to clarify both causality and timing.[4]

These findings do not show that retatrutide has the same hair-loss risk or the same underlying mechanism as Wegovy®. They do indicate that hair shedding deserves consideration across weight-loss treatments, especially when weight loss is substantial or occurs over a relatively short period.

Can Hair Loss Be Prevented or Reduced While Taking Retatrutide?

Because retatrutide is still investigational, there is no established protocol for preventing hair loss during its use. A more appropriate clinical approach is to look for factors that may be contributing to shedding. These include the rate and extent of weight loss, overly restrictive calorie intake, inadequate protein or energy consumption, and possible deficiencies in iron, zinc, or other nutrients when clinically indicated. Concurrent medications, underlying medical conditions, and pre-existing forms of alopecia should also be considered before attributing hair loss solely to weight reduction.[3][4]

Supplements should not be recommended without evidence of a deficiency or another clear clinical reason. Too much of certain vitamins or minerals can also affect overall health and contribute to hair shedding. Adequate nutrition and avoidance of severe dietary restriction may help limit additional metabolic stress during significant weight loss, although they cannot eliminate the risk of shedding in everyone.

Will Hair Grow Back? What Research Indicates About Recovery

In telogen effluvium, the hair follicles usually remain intact and capable of producing new growth. The condition temporarily shifts more follicles into the resting and shedding phases rather than permanently damaging them. Once the underlying stressor resolves or stabilizes, the follicles can gradually return to the active growth phase.[3][6]

Recovery takes time. Shedding may continue for several months, and visible regrowth often appears later because scalp hair grows slowly. The pace and extent of recovery can depend on several factors, including whether weight and nutritional intake have stabilized, how long the triggering stress lasted, nutrient status, thyroid and hormonal health, age, genetic predisposition, and the presence of pre-existing pattern hair loss.

Telogen effluvium may also make previously subtle androgenetic alopecia more noticeable. In these cases, the acute shedding may improve while underlying thinning remains. Professionals should therefore assess the pattern and cause of hair loss rather than assuming every case is temporary or directly related to retatrutide.

The contents of this page are meant for licensed medical professionals. They serve informational purposes only and are not to be taken as medical advice.

Citations

[1] Eli Lilly and Company. Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial. Published May 21, 2026. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss

[2] Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526.  https://www.nejm.org/doi/full/10.1056/NEJMoa2301972

[3] Kang DH, Kwon SH, Sim WY, Lew BL. Telogen Effluvium Associated With Weight Loss: A Single Center Retrospective Study. Ann Dermatol. 2024;36(6):384-388. https://pubmed.ncbi.nlm.nih.gov/39623615/

[4] Gupta AK, Teasell EM, Economopoulos V, Mirmirani P. GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling. Sci Prog. 2026;109(2):368504261444578. https://pubmed.ncbi.nlm.nih.gov/41998799/

[5] US Food and Drug Administration. WEGOVY® (semaglutide) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215256s011lbl.pdf [6] Malkud S. Telogen Effluvium: A Review. J Clin Diagn Res. 2015;9(9):WE01-WE3. doi:10.7860/JCDR/2015/15219.6492